Second-line and salvage therapies for steroid-refractory acute graft-versus-host disease: an integrated synthesis of current evidence and clinical sequencing. (PubMed, Curr Opin Hematol) - Sep 1, 2026 - "We propose an evidence-based clinical sequencing algorithm that integrates ruxolitinib, MSCs, extracorporeal photopheresis (ECP), mTOR-targeted salvage, ATG, and clinical trial enrollment and supportive-care priorities, including infectious prophylaxis and organ-specific management."
Journal • Acute Graft versus Host Disease • Bone Marrow Transplantation • Graft versus Host Disease • Immunology • Oncology • Transplantation • JAK1 • JAK2 • REG3A • ST2
|
|
Alexandros Kanelopoulos; Emmanouil Nikolousis; Julieta Zuluaga
|